T1	Participants 65 121	postmenopausal patients with metastatic breast carcinoma
T2	Participants 212 275	Breast cancer patients with prior response to endocrine therapy
T3	Participants 446 588	post menopausal patients who had disease progression after receiving antiestrogen therapy either for metastatic disease or as adjuvant therapy
T4	Participants 642 669	683 postmenopausal patients
T5	Participants 1703 1759	postmenopausal patients with metastatic breast carcinoma
